🇺🇸 FDA
Pipeline program

Wegovy 0.25 mg FlexTouch solution for injection in pre-filled pen, Wegovy 1 mg FlexTouch solution for injection in pre-filled pen, Wegovy 0.5 mg FlexTouch solution for injection in pre-filled pen, Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen, Wegovy 1.7 mg FlexTouch solution for injection in pre-filled pen

NN9536-7752

Approved small_molecule active

Quick answer

Wegovy 0.25 mg FlexTouch solution for injection in pre-filled pen, Wegovy 1 mg FlexTouch solution for injection in pre-filled pen, Wegovy 0.5 mg FlexTouch solution for injection in pre-filled pen, Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen, Wegovy 1.7 mg FlexTouch solution for injection in pre-filled pen for Obesity is a Approved program (small_molecule) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).

Program details

Company
Novo Nordisk A/S
Indication
Obesity
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials